<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>REGULATORY OVERLORD CHRONICLES</title>
	<link>http://regulatoryoverlord.com/blog</link>
	<description>All Things Regulatory &#38; Legal for Drugs, Biologics, Medical Devices, Nanotechnology and Combination Products.</description>
	<lastBuildDate>Wed, 09 Dec 2009 21:16:55 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.0.4" -->

	<item>
		<title>The Chasmic Shift in Disruptive Business Climates</title>
		<description><![CDATA[The Chasmic Shift in Disruptive Business Climates for the medical products industry and issues of healthcare reform.]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/12/10/the-chasmic-shift-in-disruptive-business-climates/</link>
			</item>
	<item>
		<title>Talkback: Response to Article in Nature, A To-Do List for the New FDA Commissioner, by Susan Okie, M.D.</title>
		<description><![CDATA[A Response to Article in Nature, A To-Do List for the New FDA Commissioner, by Susan Okie, M.D. ]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/06/04/talkback-response-to-article-in-nature-a-to-do-list-for-the-new-fda-commissioner-by-susan-okie-md/</link>
			</item>
	<item>
		<title>The Future of Convergent Technologies</title>
		<description><![CDATA[(Report from BIOMEDevice 2009 Executive Forum) I took time off to finalize my doctoral thesis draft and research bleeding edge companies presenting at BIOMEDevice 2009 held at Boston Convention Center on Tuesday April 21st through Wednesday, April 22, 2009. BIOMEDevice Forum is coined by the organizers Canon Communications LLC “Cancom”, as “New England&#8217;s premier executive-level [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/05/06/the-future-of-convergent-technologies-report-from-biomedevice-2009-executive-forum/</link>
			</item>
	<item>
		<title>The medical device industry and the role of CDRH</title>
		<description><![CDATA[The public trust manufacturers of medical products to develop and commercialize devices that are safe for humans. There are many types of medical devices varying in complexity, some as simple as contact lenses and others, life saving devices such as a pacemaker. In many cases these medical products perform as expected and last for the [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/04/10/the-medical-device-industry-and-the-role-of-cdrh/</link>
			</item>
	<item>
		<title>Introduction to the Nanotechnology series&#8230;&#8230;.</title>
		<description><![CDATA[The series on nanotechnology will address many important and foundational questions posed in the entry and commercialization of novel particles employing novel technology and useful in multiple applications and settings. The folowing are a few issues that come to mind. Quick Primer: 0 Prior to 2004, products using nanoparticles or nanotechnology methods were not subject [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/04/07/introduction-to-the-nanotechnology-series/</link>
			</item>
	<item>
		<title>Plan B &#8211; Feminism as Practice &amp; Theory</title>
		<description><![CDATA[Plan B &#8211; Barr Pharmaceuticals (subsidiary of Teva Pharmaceutical Industries) I thought I would step outside my comfort zone and take a look at the Plan B controversy in a feminist legal theory perspective using Levit, Nancy &#38; Robert Verchick &#38; Martha Minow&#8217;s 2006, Feminist Legal Theory: A Primer. Without going into the decision, politics [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/04/02/plan-b-feminism-as-practice-theory/</link>
			</item>
	<item>
		<title>The imbedded American notion&#8230;.</title>
		<description><![CDATA[There is an imbedded American notion that the government and the three branches are the protector, arbiter and architects of the public good. The public assumes that if the FDA allows a regulated product on the market it is synonymous with a “good housekeeping” seal and declared safe. Not all regulated products undergo pre-market review; [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/04/02/the-imbedded-american-notion/</link>
			</item>
	<item>
		<title>Reflections on law and legal foundations&#8230;..</title>
		<description><![CDATA[Among the various schools and paradigms of thought, it is difficult to assess where we are, without first exploring the history and purpose of food and drug law. The Federal Food, Drug &#38; Cosmetic (FDCA) Act was the first comprehensive federal law regulating food and drugs. It was strictly an enforcement statute and designed to [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/03/25/reflections/</link>
			</item>
	<item>
		<title>Bioslash continues…</title>
		<description><![CDATA[According to recent published reports, BioWorld Today’s research found more than 80 biotech companies cut about 5,000 jobs last year. So far this year, BioWorld has reported layoffs at 40 biotechs. A report from Burrill &#38; Co. placed the numbers higher, estimating that 100 biotechs laid off more than 6,000 employees. Nonetheless, Burrill &#38; Co. [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/03/23/bioslash-continues%e2%80%a6/</link>
			</item>
	<item>
		<title>The Policy Connection</title>
		<description><![CDATA[In Foundations of the Law, Professor’s Bailey Kuklin and Jeffrey Stempel assert that “during its history, United States law has frequently resulted from commercial, geographic, social and political conflict” (1994:138). The regulation of medical products is no different; various perspectives apply to various constituents or stakeholders. Whether one is a patient, a medical practitioner, a [...]]]></description>
		<link>http://regulatoryoverlord.com/blog/2009/03/23/the-policy-connection-3/</link>
			</item>
</channel>
</rss>

